Cullinan Therapeutics CGEM Insider Ownership

NASDAQ CGEM

$14.96 +0.13 (+0.88%)

As of: Oct 21, 2026 · 2:43 PM EDT

Insider Holdings by Owner

30.09Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

15.81%

▼-0.012% pp QoQ

Shares Held by Insiders

10.17Mn

filed for Sep 2026

▼-0.08% QoQ

Shares Outstanding

64.35Mn

64,345,770 shares

Direct Holdings

1.21Mn

Indirect: 8.96Mn

Net Shares Traded (QoQ)

-8.00K

net selling in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 16, 2026

Over the past year, CGEM insiders bought $2.97 million of stock (347.88K shares) and sold $2.41 million (158.57K shares) on the open market.

By number of insiders, Cullinan Therapeutics saw one insider buy and 5 insiders sell on the open market over the past 12 months.
Among CGEM insiders, Lynx1 Capital Management LP (10% owner) bought the most stock on the open market in the past 12 months: $2.97 million (347.88K shares), most recently on October 28, 2025.
On the selling side, Jennifer Michaelson (Chief Scientific Officer) was the top open-market seller of Cullinan Therapeutics over the past 12 months, with $1.51 million sold (89.33K shares) and the latest sale on September 8, 2026.
Away from the open market, CGEM insiders received 130.29K shares in stock awards and acquired 54K shares through option exercises and conversions over the last 12 months.
Per Business Quant data, Cullinan Therapeutics insiders hold 10.17Mn shares in total based on their latest Form 4 filings, or 15.81% of the 64.35Mn shares outstanding; that total is down 0.08% from 10.18Mn shares at the end of Q2 2026.
Indirect holdings, through trusts, partnerships, family members and other entities, make up 88.11% (8.96Mn shares) of Cullinan Therapeutics' insider total, with the other 11.89% (1.21Mn shares) held directly.
The insider holdings in Cullinan Therapeutics belong to 7 insiders who have reported on Form 4 within the past two years.
Cullinan Therapeutics' three biggest insider holders are Lynx1 Capital Management LP (10% owner, 8.96Mn shares), Nadim Ahmed (President and CEO, 390.8K shares) and Corrine Savill (Chief Business Officer, 240.99K shares), based on their latest Form 4 filings.
Lynx1 Capital Management LP alone accounts for 88.11% of the shares held by Cullinan Therapeutics insiders.
A total of 41 Form 4 filings with transactions in Cullinan Therapeutics stock were made over the past 12 months, by 13 insiders.
These insider figures for Cullinan Therapeutics are based on Form 4 filings through September 10, 2026.

Form 4 Holdings

Insiders Holding CGEM

Insiders 16

Shares held 30.09Mn

Of outstanding 46.76%

#	Insider	Position	Direct	Indirect	Total	Share of Insiders	Last Filed
1	Capital Management Lp Lynx1	TenPercentOwner	0	26,325,449	26,325,449	87.5%	30 Oct, 2025
2	Vision Scs F2	TenPercentOwner	1,255,963	0	1,255,963	4.2%	04 Aug, 2022
3	Bioscience I 2017 Ltd F2	TenPercentOwner	537,392	0	537,392	1.8%	23 Jun, 2022
4	Nadim Ahmed	President And Ceo	390,803	0	390,803	1.3%	25 Feb, 2026
5	Corrine Savill	Chief Business Officer	240,990	0	240,990	0.8%	21 Feb, 2025
6	Morana Jovan-Embiricos	TenPercentOwner	207,803	0	207,803	0.7%	28 Jun, 2022
7	Thomas Ebeling	Director	186,653	0	186,653	0.6%	11 Jun, 2024
8	Jeffrey Alan Jones	Chief Medical Officer	159,968	0	159,968	0.5%	25 Feb, 2026
9	Jennifer Michaelson	Chief Scientific Officer	158,844	0	158,844	0.5%	10 Sep, 2026
10	Jeffrey Trigilio	Chief Financial Officer	133,919	0	133,919	0.4%	23 Feb, 2024
11	Jacquelyn L Sumer	Chief Legal Officer	130,559	0	130,559	0.4%	02 Jul, 2026
12	Mary Kay Fenton	Chief Financial Officer	127,921	0	127,921	0.4%	02 Jul, 2026
13	Patrick Baeuerle	Chief Scientific Officer	76,000	0	76,000	0.3%	21 Feb, 2023
14	Leigh Zawel	Officer	69,785	0	69,785	0.2%	15 Feb, 2022
15	Partners L P/Il Bvf	TenPercentOwner	64,161	0	64,161	0.2%	19 Jan, 2023
16	Raymond T Keane	Chief Legal Officer	24,124	0	24,124	0.1%	15 Feb, 2022

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

438 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
08 Sep, 2026	Jennifer Michaelson	Chief Scientific Officer	Acquired M	4,000	$4.30	$17.20K	166,844	Direct
08 Sep, 2026	Jennifer Michaelson	Chief Scientific Officer	Disposed S	8,000	$21.57	$172.56K	158,844	Direct
08 Sep, 2026	Jennifer Michaelson	Chief Scientific Officer	Disposed M	4,000	$0.00	$0	78,987	Direct
13 Aug, 2026	Jennifer Michaelson	Chief Scientific Officer	Acquired M	30,000	$4.30	$129.00K	192,844	Direct
13 Aug, 2026	Jennifer Michaelson	Chief Scientific Officer	Disposed S	30,000	$20.26	$607.80K	162,844	Direct
13 Aug, 2026	Jennifer Michaelson	Chief Scientific Officer	Disposed M	30,000	$0.00	$0	82,987	Direct
06 Jul, 2026	Jennifer Michaelson	Chief Scientific Officer	Acquired M	4,000	$4.30	$17.20K	170,844	Direct
06 Jul, 2026	Jennifer Michaelson	Chief Scientific Officer	Disposed S	8,000	$17.82	$142.56K	162,844	Direct
06 Jul, 2026	Jennifer Michaelson	Chief Scientific Officer	Disposed M	4,000	$0.00	$0	112,987	Direct
30 Jun, 2026	Mary Kay Fenton	Chief Financial Officer	Acquired A	1,541	$8.60	$13.25K	127,921	Direct
30 Jun, 2026	Jacquelyn L Sumer	Chief Legal Officer	Acquired A	2,470	$8.60	$21.24K	130,559	Direct
16 Jun, 2026	Stephen W Webster	Director	Acquired A	25,319	$0.00	$0	25,319	Direct
16 Jun, 2026	Mittie Doyle	Director	Acquired A	21,781	$0.00	$0	21,781	Direct
16 Jun, 2026	Anthony Rosenberg	Director	Acquired A	25,319	$0.00	$0	25,319	Direct
16 Jun, 2026	David D. Meek	Director	Acquired A	25,319	$0.00	$0	25,319	Direct
16 Jun, 2026	Mary Thistle	Director	Acquired A	25,319	$0.00	$0	25,319	Direct
16 Jun, 2026	Andrew R Allen	Director	Acquired A	21,781	$0.00	$0	21,781	Direct
05 May, 2026	Jennifer Michaelson	Chief Scientific Officer	Acquired M	4,000	$4.30	$17.20K	174,844	Direct
05 May, 2026	Jennifer Michaelson	Chief Scientific Officer	Disposed S	7,800	$14.60	$113.88K	167,044	Direct
05 May, 2026	Jennifer Michaelson	Chief Scientific Officer	Disposed S	200	$15.58	$3.12K	166,844	Direct

Showing 1 to 20 of 438 transactions